Loading data for VCYT — first visit, this takes a few seconds.

アラート

Veracyte Inc. (VCYT)

NasdaqGM: VCYT · リアルタイム株価 · USD

41.48

+0.80 (1.97%)

終値時点： Aug 18, 2026, 3:59 PM

1.97% (1D)

買気配	33.3
時価総額	3.33B
売上高（TTM）	561.9M
純利益（TTM）	114.48M
ベータ	1.94
EPS（TTM）	1.4
PER（TTM）	29.6
予想PER	21.27
PBR（TTM）	2.51
PSR（TTM）	5.93
Earnings Date	Nov 3, 2026

売気配	59.52
出来高	428,486
平均出来高（20日）	1,334,545
始値	41.92
前日終値	40.68
当日レンジ	40.09 - 42.46
52週レンジ	28.25 - 60.91
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

VCYTについて

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nC...

[続きを読む]

業種 Diagnostics & Research

セクター Healthcare

IPO日 Oct 30, 2013

従業員数 755

上場取引所 NasdaqGM

ティッカー VCYT

ウェブサイト https://www.veracyte.com

企業情報の全文

業績

2025年のVeracyteの売上高は517.14Mで、前年の445.76Mから16.01%の増加でした。利益は66.35Mで、174.89%の増加でした。

財務諸表

決算サプライズ

VeracyteはJul 30, 2026に四半期決算を発表しました：

売上高は $150.32M で、予想を下回りました $0, うち 15.49% の前年比増加にあたります.

EPSは 0.54 で、予想を上回りました 0.11, うち 22.73% の前年比増加にあたります.

次回決算発表

Veracyte Inc.の決算発表予定日は Nov 3, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

2週間前 · MarketBeat

Veracyte Q2 Earnings Call Highlights

Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD r...

2週間前 · Simply Wall St.

Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?

Veracyte (VCYT) is back in focus after raising its 2026 revenue guidance to a range of US$590 million to US$596 million, and releasing detailed second quarter and first half earnings results. See our ...

2週間前 · GuruFocus.com

Veracyte Inc (VCYT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Launches ...

Veracyte Inc (VCYT) raises full-year guidance after delivering 15% revenue growth and launching Prosigna and TrueMRD, positioning for long-term expansion.

2週間前 · Zacks

Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of +25.58% and +4.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2週間前 · Insider Monkey

Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S. market saw a...

2ページ中1ページ

Veracyte Inc. (VCYT)